secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001641172-25-016574
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology enters $587,905 stock purchase agreement with Prevail Partners for Phase 3 THIO trial
--------------------------------------------------------------------------------

- Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.
- Share price set at 120% of 30-day VWAP; minimum share price of $1.74; maximum shares issuable at minimum price: 337,876.
- Shares are unregistered, issued under Section 4(a)(2); subject to 19.99% blocker and Exchange Cap.
- Proceeds used to fund a multicenter Phase 3 study of THIO sequenced with cemiplimab in advanced NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225016574/0001641172-25-016574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225016574/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer